Calidi Biotherapeutics (NYSE American: CLDI) has entered a collaboration with TransferAI, a private Austin-based AI company, to apply agentic AI orchestration to the IND submission process for CLD-401, its lead oncolytic virotherapy candidate. The arrangement gives Calidi access to TransferAI's Sofie platform, which is described by the company as purpose-built for biopharma regulatory workflows including research coordination, cross-referencing, drafting, and multi-step review activities. CLD-401 is currently in IND-enabling studies, with Calidi targeting an IND filing by year-end 2026. Financial terms were not disclosed.
CLD-401 is the lead program from Calidi's RedTail platform, which the company describes as a systemically delivered oncolytic virotherapy approach built on a genetically engineered, enveloped vaccinia virus. The platform is designed to address a longstanding barrier in oncolytic virus development: immune clearance of the virus in circulation before it can reach tumor sites. Calidi engineers the vaccinia virus to incorporate a chimeric CD55 receptor into the viral envelope, which the company says shields the virus from complement-mediated destruction and allows systemic intravenous delivery to metastatic lesions. Most approved oncolytic virus therapies, including Amgen's Imlygic (talimogene laherparepvec), require direct intratumoral injection and cannot reach disseminated disease.
Once at the tumor site, CLD-401 is engineered to replicate selectively within cancer cells and express an IL-15 superagonist payload. IL-15 is a cytokine with established activity in activating CD8+ T cells, NK cells, and gamma delta T cells, and its superagonist form has been studied in published literature as a mechanism for amplifying anti-tumor immune responses within the tumor microenvironment. CLD-401's target indications include non-small cell lung cancer, head and neck cancer, and other solid tumor types.
Deal context
TransferAI's Sofie platform operates as an agentic AI system, meaning it uses autonomous AI agents to execute and coordinate multi-step regulatory tasks within defined parameters, rather than functioning as a conventional AI writing or search tool. For IND submissions, which require precision across chemistry, manufacturing, and controls documentation, preclinical data compilation, and FDA-formatted regulatory packages, the platform is positioned as an orchestration layer that works alongside Calidi's existing clinical and regulatory teams rather than replacing them.